Q-omics provides the consensus-scored ZNF488 profile across patient tissues and cancer cell-line models. ZNF488 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF488 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ZNF488 RNA expression shows 16,918 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where ZNF488 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF488 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF488 survival associations across molecular data types. ZNF488 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF488 RNA expression–survival associations across cancer types. High ZNF488 expression shows unfavorable associations in KIRP, PAAD, ACC, SKCM, LUAD and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF488 RNA expression.
This table summarizes ZNF488 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF488. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF488 shows lower tumor expression in THCA, KIRP, KIRC and BRCA and higher tumor expression in BLCA and LUSC. The BLCA box plot shows higher ZNF488 RNA expression in tumor versus normal tissue (log2 FC = +2.284, t-test p < 0.001).
This table shows molecular features associated with ZNF488 in patient tissues and cancer cell lines. In patient samples, ZNF488 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF488 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
